Plasma β-amyloid (Aβ) 40 concentration, lipid status and age in humans

被引：16

作者：

Smith, CCT ^{[1
]}

Betteridge, DJ ^{[1
]}

机构：

[1] UCL Royal Free & Univ Coll Med Sch, Middlesex Hosp, Sir Jules Thorn Inst, Dept Med, London W1N 8AA, England

来源：

NEUROSCIENCE LETTERS | 2004年 / 367卷 / 01期

关键词：

hyperlipidaemia; age; beta-amyloid; Alzheimer's disease;

D O I：

10.1016/j.neulet.2004.05.081

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

The circulation constitutes a potential source of the beta-amyloid (Abeta) protein deposited cerebrally in Alzheimer's disease (AD). Cardiovascular risk factors, including hyperlipidaemia, may be involved in the pathogenesis of AD. Plasma Abeta 40 was measured by radioimmunoassay in normal and hyperlipidaemic subjects with the aim of determining if plasma lipid content and/or age correlated with circulating Abeta 40 concentration. Plasma Abeta 40 levels in hyperlipidaemics were elevated by 20.3% compared to normal subjects. Abeta 40 did not correlate with plasma lipids in normal subjects. Age, however, correlated positively with Abeta 40 in these individuals and with total cholesterol, low-density lipoprotein (LDL) and triglycerides. No correlations were observed in hyperlipidaemic patients or when the data for the two groups were combined. These data are consistent with ageing, the primary risk factor for AD, but not hyperlipidaemia influencing circulating Abeta 40 levels. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

引用

收藏

页码：48 / 50

页数：3

相关论文

共 17 条

[1] Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma [J].

Biere, AL ;

Ostaszewski, B ;

Stimson, ER ;

Hyman, BT ;

Maggio, JE ;

Selkoe, DJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (51) :32916-32922

[2]

Bodovitz S, 1996, J BIOL CHEM, V271, P4436

[3]

Carr D. B., 1997, American Journal of Medicine, V103, p3S, DOI 10.1016/S0002-9343(97)00262-3

[4] PLATELETS ARE THE PRIMARY SOURCE OF AMYLOID BETA-PEPTIDE IN HUMAN BLOOD [J].

CHEN, M ;

INESTROSA, NC ;

ROSS, GS ;

FERNANDEZ, HL .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 213 (01) :96-103

[5] Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo [J].

Fassbender, K ;

Simons, M ;

Bergmann, C ;

Stroick, M ;

Lütjohann, D ;

Keller, P ;

Runz, H ;

Kühl, S ;

Bertsch, T ;

von Bergmannn, K ;

Hennerici, M ;

Beyreuther, K ;

Hartmann, T .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (10) :5856-5861

[6] The role of cholesterol in the biosynthesis of β-amyloid. [J].

Frears, ER ;

Stephens, DJ ;

Walters, CE ;

Davies, H ;

Austen, BM .

NEUROREPORT, 1999, 10 (08) :1699-1705

[7] AMYLOID DEPOSITION AS THE CENTRAL EVENT IN THE ETIOLOGY OF ALZHEIMERS-DISEASE [J].

HARDY, J ;

ALLSOP, D .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1991, 12 (10) :383-388

[8] LIPOPROTEIN-CHOLESTEROL DISTRIBUTIONS IN SELECTED NORTH-AMERICAN POPULATIONS - LIPID RESEARCH CLINICS PROGRAM PREVALENCE STUDY [J].

HEISS, G ;

TAMIR, I ;

DAVIS, CE ;

TYROLER, HA ;

RIFKIND, BM ;

SCHONFELD, G ;

JACOBS, D ;

FRANTZ, ID .

CIRCULATION, 1980, 61 (02) :302-315

[9] Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-β (Aβ) 40 or Aβ 42 in humans [J].

Ishii, K ;

Tokuda, T ;

Matsushima, T ;

Miya, F ;

Shoji, S ;

Ikeda, S ;

Tamaoka, A .

NEUROSCIENCE LETTERS, 2003, 350 (03) :161-164

[10] Amyloid-β peptides interact with plasma proteins and erythrocytes:: Implications for their quantitation in plasma [J].

Kuo, YM ;

Kokjohn, TA ;

Kalback, W ;

Luehrs, D ;

Galasko, DR ;

Chevallier, N ;

Koo, EH ;

Emmerling, MR ;

Roher, AE .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 268 (03) :750-756